Mohammad M. Mahmoud

Urology

747 N Rutledge St Fl 5
Springfield, IL 62702

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Quality and Readability of Online Health Information on Common Urologic Cancers: Assessing Barriers to Health Literacy in Urologic Oncology.

Quality and Readability of Online Health Information on Common Urologic Cancers: Assessing Barriers to Health Literacy in Urologic Oncology.

Journal: Urology practice

Published: June 20, 2024

Reply by Authors.

Reply by Authors.

Journal: Urology practice

Published: June 20, 2024

Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 02, 2023

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

Journal: European urology

Published: September 06, 2022

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2022

Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns.

Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns.

Journal: Urologic oncology

Published: April 15, 2022

Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?

Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?

Journal: Urologic oncology

Published: September 26, 2021

The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.

The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.

Journal: Urologic oncology

Published: September 03, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026